STOCK TITAN

[Form 4] BIO-TECHNE Corp Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bio-Techne Corporation CFO James Hippel reported routine equity compensation activity. On April 22, 2026, he exercised stock options to acquire 62,000 shares of common stock at an exercise price of $47.60 per share. In a related F-code tax-withholding disposition, 56,097 shares of common stock were delivered at $58.58 per share to cover obligations. Following these transactions, Hippel directly owned 204,722 Bio-Techne common shares and retained substantial unexercised stock options and restricted stock units with vesting schedules extending through 2028.

Positive

  • None.

Negative

  • None.
Insider Hippel James
Role CFO
Type Security Shares Price Value
Exercise Stock Options (Right to Buy) 62,000 $0.00 --
Exercise Common Stock 62,000 $0.00 --
Tax Withholding Common Stock 56,097 $58.58 $3.29M
holding Stock Options (Right to Buy) -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Performance Restricted Stock Units -- -- --
holding Performance Stock Options (Right to Buy) -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Performance Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Restricted Stock Units -- -- --
holding Performance Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Stock Options (Right to Buy) -- -- --
Holdings After Transaction: Stock Options (Right to Buy) — 124,068 shares (Direct, null); Common Stock — 204,722 shares (Direct, null); Performance Restricted Stock Units — 13,865 shares (Direct, null); Performance Stock Options (Right to Buy) — 37,314 shares (Direct, null); Restricted Stock Units — 4,010 shares (Direct, null)
Footnotes (1)
  1. Fully exercisable. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028. 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Options exercised 62,000 shares Common stock acquired via option exercise on April 22, 2026
Option exercise price $47.60/share Exercise price for 62,000 stock options
Tax-withholding shares 56,097 shares F-code disposition to cover obligations at $58.58/share
Tax-withholding price $58.58/share Price for 56,097 common shares delivered for tax/payment
Shares held after 204,722 shares Direct Bio-Techne common stock ownership after transactions
Options remaining (grant) 124,068 options Stock options remaining from the 47.60 exercise-price grant
Largest remaining option block 167,328 options Stock options at $66.97 exercise price expiring August 5, 2027
Restricted Stock Units financial
"security_title: "Restricted Stock Units" with underlying common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"security_title: "Performance Restricted Stock Units" tied to performance goals"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
tax-withholding disposition financial
"transaction_action: "tax-withholding disposition" for F-code common stock entry"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" for M-code entries"
Stock Options (Right to Buy) financial
"security_title: "Stock Options (Right to Buy)" with exercise prices and expirations"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hippel James

(Last)(First)(Middle)
614 MCKINLEY PLACE NE

(Street)
MINNEAPOLIS MINNESOTA 55413

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/22/2026M62,000A$0204,722D
Common Stock04/22/2026F56,097D$58.58148,625D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$47.604/22/2026M62,000 (1)08/07/2026Common Stock62,000$0124,068D
Stock Options (Right to Buy)$66.97 (1)08/05/2027Common Stock167,328167,328D
Stock Options (Right to Buy)$120.46 (1)08/06/2028Common Stock40,53640,536D
Stock Options (Right to Buy)$94.52 (3)08/15/2029Common Stock45,22045,220D
Performance Restricted Stock Units(2) (4) (4)Common Stock13,86513,865D
Performance Stock Options (Right to Buy)$84.61 (4)08/15/2030Common Stock37,31437,314D
Stock Options (Right to Buy)$84.61 (5)08/15/2030Common Stock45,92345,923D
Performance Restricted Stock Units(2) (6) (6)Common Stock24,06224,062D
Restricted Stock Units(2) (7) (7)Common Stock4,0108,021D
Stock Options (Right to Buy)$74.91 (8)08/15/2034Common Stock32,41732,417D
Restricted Stock Units(2) (9) (9)Common Stock23,08923,089D
Performance Restricted Stock Units(2) (10) (10)Common Stock29,42029,420D
Restricted Stock Units(2) (11) (11)Common Stock14,71014,710D
Stock Options (Right to Buy)$53.6 (12)08/15/2035Common Stock37,63237,632D
Explanation of Responses:
1. Fully exercisable.
2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
3. Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
4. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
5. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
6. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
7. 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027.
8. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
9. 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
11. 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
12. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
/s/ Andrew Nick as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed04/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Bio-Techne (TECH) CFO James Hippel report in this Form 4?

CFO James Hippel reported routine equity compensation activity. He exercised stock options for 62,000 Bio-Techne common shares and had 56,097 shares withheld in an F-code tax transaction, ending with 204,722 shares held directly after the transactions.

How many Bio-Techne shares did the CFO acquire through option exercises?

James Hippel exercised stock options to acquire 62,000 shares of Bio-Techne common stock. The options carried an exercise price of $47.60 per share, converting a derivative position into direct share ownership as part of his compensation-related holdings.

What is the tax-withholding transaction disclosed for BIO-TECHNE Corp (TECH)?

The filing shows an F-code tax-withholding disposition of 56,097 Bio-Techne common shares at $58.58 per share. These shares were delivered to satisfy exercise price or tax liabilities tied to the same equity compensation activity, not an open-market sale by the CFO.

How many Bio-Techne shares does CFO James Hippel hold after these transactions?

After the reported transactions, James Hippel directly holds 204,722 shares of Bio-Techne common stock. This figure reflects his updated non-derivative ownership following the 62,000-share option exercise and the related 56,097-share tax-withholding disposition reported in the Form 4.

What derivative awards does the Bio-Techne CFO still hold after the Form 4 events?

The filing lists multiple remaining derivative awards, including stock options and restricted stock units on Bio-Techne common stock. Examples include 167,328 options at a $66.97 exercise price expiring in 2027 and 45,220 options at $94.52 expiring in 2029, plus various RSU and performance RSU grants.

Are the Bio-Techne (TECH) Form 4 transactions open-market buys or sales?

No open-market purchases or sales are shown. The key transactions are an M-code option exercise acquiring 62,000 shares and an F-code tax-withholding disposition of 56,097 shares, both tied to equity compensation rather than discretionary market trading by the CFO.